Skip to main content

What the FDA labels say about taking them together

Amiodarone and thalidomide

Thalidomide's FDA label of March 24, 2023 names amiodarone in its drug interactions section; the amiodarone labels PlainMeds reads (2) do not name thalidomide.

Check it at the source: the amiodarone FDA label on DailyMed (effective December 9, 2025, Chartwell RX, LLC); the thalidomide FDA label on DailyMed (effective March 24, 2023, Celgene Corporation).

What does the amiodarone label say about thalidomide?

Amiodarone's label (effective December 9, 2025) and its 1 other brand-application label do not name thalidomide in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Amiodarone Hydrochloride), Chartwell RX, LLC, effective December 9, 2025 (SPL set 5520f11d-968d-4f4f-bf57-d14369c0d746), via openFDA; the full label on DailyMed

What does the thalidomide label say about amiodarone?

Thalidomide label, drug interactions

Drugs which Cause Peripheral Neuropathy The use of drugs which cause peripheral neuropathy (e.g., bortezomib, amiodarone, cisplatin, docetaxel, paclitaxel, vincristine, disulfiram, phenytoin, metronidazole, alcohol) can cause an additive effect and should be used with caution.

Source: FDA drug label (Thalomid), NDA020785 (Bristol-Myers), as published by Celgene Corporation, effective March 24, 2023 (SPL set 2eda833b-1357-4ed4-a093-194524fcb061), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

32Amiodarone generic labelers
0Thalidomide generic labelers
AmiodaroneThalidomide
Labeled forn/aLeukemia, lymphoma and myeloma
Boxed warningYesYes
Pharmacy cost (NADAC)$0.122 per tablet 200 mg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?